{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:05:08Z","timestamp":1790831108028,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004846","name":"Beijing University of Chinese Medicine","doi-asserted-by":"publisher","award":["2023\u2010JYB\u2010XJSJJ001"],"award-info":[{"award-number":["2023\u2010JYB\u2010XJSJJ001"]}],"id":[{"id":"10.13039\/501100004846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004846","name":"Beijing University of Chinese Medicine","doi-asserted-by":"publisher","award":["2023\u2010ZXFZJJ\u2010JW\u2010001"],"award-info":[{"award-number":["2023\u2010ZXFZJJ\u2010JW\u2010001"]}],"id":[{"id":"10.13039\/501100004846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp; Metabol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To characterize the global development, collaboration structure, publication landscape, citation influence and thematic evolution of research on selective GLP\u20101 receptor agonists and GLP\u20101\u2013based multi\u2010receptor agonists in T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A bibliometric analysis was conducted on 3736 original articles published between 2004 and 2025 and retrieved from the Web of Science Core Collection. Publication trends, research contributions, collaboration networks, citation impact and thematic evolution were evaluated using complementary bibliometric indicators and network analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Annual publication output increased substantially. Selective\u2010only studies remained the cumulative core of the evidence base, while mixed\/comparative and multi\u2010receptor\u2010only studies expanded rapidly in recent years. The United States led in research output and international connectivity, and Novo Nordisk and Eli Lilly were the most prominent institutional contributors based on author affiliation analysis. Diabetes, Obesity and Metabolism was the leading source journal. Research output was highly concentrated across countries but more widely distributed across institutions and authors. Thematic emphasis shifted from incretin biology and glycemic efficacy toward cardiovascular and kidney outcomes, obesity, integrated treatment strategies and real\u2010world evidence. Major trials, particularly LEADER and REWIND, and ADA\/EASD consensus statements exerted strong citation influence. Sensitivity analysis supported the overall robustness of the principal findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Research on GLP\u20101\u2013based agonists in T2DM has expanded rapidly and shifted toward an integrated cardiovascular\u2013kidney\u2013metabolic framework. Studies of selective GLP\u20101RAs remain central to the literature, while studies of newer GLP\u20101\u2013based multi\u2010receptor agonists are contributing to its diversification. Evidence remains comparatively less developed for longer\u2010term outcomes of emerging agents, treatment sustainability in routine care, patient experience and diverse populations and settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70351","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:52:37Z","timestamp":1790830357000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global Landscape and Thematic Evolution of Selective\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonists and\n                    <scp>GLP<\/scp>\n                    \u20101\u2013Based Multi\u2010Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-1010","authenticated-orcid":false,"given":"Yanbing","family":"Wang","sequence":"first","affiliation":[{"name":"Health Management Program Boston University  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3180-6635","authenticated-orcid":false,"given":"Zhanru","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-4562","authenticated-orcid":false,"given":"Shifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Chinese Materia Medica Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5100-2364","authenticated-orcid":false,"given":"Cuiyan","family":"Lv","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Traditional Chinese Medicine Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-6690","authenticated-orcid":false,"given":"Hesham R.","family":"El\u2010Seedi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science Islamic University of Madinah  Madinah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7108-2897","authenticated-orcid":false,"given":"Shaden A. M.","family":"Khalifa","sequence":"additional","affiliation":[{"name":"Neurology and Psychiatry Department Capio Saint G\u00f6ran's Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9231-3869","authenticated-orcid":false,"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025"},{"issue":"1","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-021-01289-4","article-title":"Variability of Risk Factors and Diabetes Complications","volume":"20","author":"Ceriello A.","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: A Multinational, Cross\u2010Sectional Study of Cardiovascular Disease Prevalence in Adults With Type 2 Diabetes Across 13 Countries","volume":"20","author":"Mosenzon O.","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"9","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jama.2020.10771","article-title":"Payer Mix Among Patients Receiving Dialysis","volume":"324","author":"Lin E.","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why Does Obesity Cause Diabetes?","volume":"34","author":"Klein S.","year":"2022","journal-title":"Cell Metabolism"},{"issue":"2","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12020-023-03547-9","article-title":"BEYOND 2\u2009Years: Durability of Metabolic Benefits by Simplification of Complex Insulin Regimens in Type 2 Diabetes","volume":"83","author":"Giugliano D.","year":"2024","journal-title":"Endocrine"},{"issue":"18","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison","volume":"79","author":"Kelsey M. D.","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and Renal Outcomes of Glucagon\u2010Like Peptide 1 Receptor Agonists Among Patients With and Without Type 2 Diabetes Mellitus: A Meta\u2010Analysis of Randomized Placebo\u2010Controlled Trials","volume":"18","author":"Rivera F. B.","year":"2024","journal-title":"American Journal of Preventive Cardiology"},{"issue":"1","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed N. A.","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12982-025-00445-5","article-title":"Optimizing Patient Education for Sustainable Self\u2010Management in Type 2 Diabetes","volume":"22","author":"Alum E. U.","year":"2025","journal-title":"Discover Public Health"},{"issue":"4","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3791","article-title":"Adherence to GLP1\u2010RA and SGLT2\u2010I Affects Clinical Outcomes and Costs in Patients With Type 2 Diabetes","volume":"40","author":"Ciardullo S.","year":"2024","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"issue":"11","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2025.5956","article-title":"Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review","volume":"334","author":"Kalyani R. R.","year":"2025","journal-title":"JAMA"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin Hormones: Their Role in Health and Disease","volume":"20","author":"Nauck M. A.","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of Exenatide (Exendin\u20104) on Glycemic Control Over 30\u2009Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea","volume":"28","author":"Kendall D. M.","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of Exenatide (Exendin\u20104) on Glycemic Control and Weight Over 30\u2009Weeks in Metformin\u2010Treated Patients With Type 2 Diabetes","volume":"28","author":"DeFronzo R. A.","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of Exenatide (Exendin\u20104) on Glycemic Control Over 30\u2009Weeks in Sulfonylurea\u2010Treated Patients With Type 2 Diabetes","volume":"27","author":"Buse J. B.","year":"2004","journal-title":"Diabetes Care"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP\u20101 Receptor Agonists in the Treatment of Type 2 Diabetes\u2010State\u2010Of\u2010The\u2010Art","volume":"46","author":"Nauck M. A.","year":"2020","journal-title":"Molecular Metabolism"},{"issue":"1","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes the LEAD (Liraglutide Effect and Action in Diabetes)\u20102 Study","volume":"32","author":"Nauck M.","year":"2009","journal-title":"Diabetes Care"},{"issue":"9683","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide Once a Day Versus Exenatide Twice a Day for Type 2 Diabetes: A 26\u2010Week Randomised, Parallel\u2010Group, Multinational, Open\u2010Label Trial (LEAD\u20106)","volume":"374","author":"Buse J. B.","year":"2009","journal-title":"Lancet"},{"issue":"9662","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide Versus Glimepiride Monotherapy for Type 2 Diabetes (LEAD\u20103 Mono): A Randomised, 52\u2010Week, Phase III, Double\u2010Blind, Parallel\u2010Treatment Trial","volume":"373","author":"Garber A.","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a Once\u2010Daily Human GLP\u20101 Analogue, Added to a Sulphonylurea Over 26\u2009Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared With Adding Rosiglitazone or Placebo in Subjects With Type 2 Diabetes (LEAD\u20101 SU)","volume":"26","author":"Marre M.","year":"2009","journal-title":"Diabetic Medicine"},{"issue":"6","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient\u2010Centered Approach","volume":"35","author":"Inzucchi S. E.","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient\u2010Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi S. E.","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso S. P.","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes","volume":"391","author":"Perkovic V.","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"10193","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double\u2010Blind, Randomised Placebo\u2010Controlled Trial","volume":"394","author":"Gerstein H. C.","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/dom.13645","article-title":"FDA Guidance on Antihyperglyacemic Therapies for Type 2 Diabetes: One Decade Later","volume":"21","author":"McGuire D. K.","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes","volume":"385","author":"Fr\u00edas J. P.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10402","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT\u20102): A Double\u2010Blind, Randomised, Multicentre, Placebo\u2010Controlled, Phase 3 Trial","volume":"402","author":"Garvey W. T.","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients With Obesity\u2010Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod M. N.","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"10278","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Doubleblind, Double\u2010Dummy, Placebo\u2010Controlled, Phase 3 Trial","volume":"397","author":"Davies M.","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High\u2010Risk Type 2 Diabetes","volume":"392","author":"McGuire D. K.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual\u2010Labeled GLP\u20101 Receptor Agonists Among US Adults With Overweight or Obesity","volume":"8","author":"Rodriguez P. J.","year":"2025","journal-title":"JAMA Network Open"},{"issue":"23","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients With Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer M. A.","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once\u2010Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman R. R.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"10157","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double\u2010Blind, Randomised Placebo\u2010Controlled Trial","volume":"392","author":"Hernandez A. F.","year":"2018","journal-title":"Lancet"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20102025","volume":"48","author":"Amer Diabet Assoc Prof Practice, C","year":"2025","journal-title":"Diabetes Care"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20102025","volume":"48","author":"Elsayed N. A.","year":"2025","journal-title":"Diabetes Care"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20102025","volume":"48","author":"Elsayed N. A.","year":"2025","journal-title":"Diabetes Care"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20102025","volume":"48","author":"AmerDiabetAssocProfessionalPractice","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal B.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD Development and Therapeutic Strategies","volume":"24","author":"Friedman S. L.","year":"2018","journal-title":"Nature Medicine"},{"issue":"8","key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/01410768231198442","article-title":"Racial, Ethnic and Regional Differences in the Effect of Sodium\u2010Glucose Co\u2010Transporter 2 Inhibitors and Glucagon\u2010Like Peptide 1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Systematic Review and Meta\u2010Analysis of Cardiovascular Outcome Trials","volume":"117","author":"Kunutsor S. K.","year":"2024","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"24","key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls S. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"10401","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP\u20101 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double\u2010Blind, Placebo and Active\u2010Controlled, Parallel\u2010Group, Phase 2 Trial Conducted in the USA","volume":"402","author":"Rosenstock J.","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose\u2010Response Effects on HbA1c and Bodyweight Reduction of Survodutide, a Dual Glucagon\/GLP\u20101 Receptor Agonist, Compared With Placebo and Open\u2010Label Semaglutide in People With Type 2 Diabetes: A Randomised Clinical Trial","volume":"67","author":"Bl\u00fcher M.","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP\u20101 Receptor Agonist Discontinuation Among Patients With Obesity and\/or Type 2 Diabetes","volume":"7","author":"Do D.","year":"2024","journal-title":"JAMA Network Open"},{"issue":"5","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.pcd.2024.06.013","article-title":"Adherence and Persistence Among People With Type 2 Diabetes Newly Initiating Oral Semaglutide Versus DPP\u20104is in a US Real\u2010World Setting","volume":"18","author":"Lv L.","year":"2024","journal-title":"Primary Care Diabetes"},{"issue":"2","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients' Experiences With GLP1\u2010RAs \u2010 a Systematic Review","volume":"43","author":"Ibsen C. K.","year":"2025","journal-title":"Scandinavian Journal of Primary Health Care"},{"issue":"3","key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00125-023-06052-w","article-title":"Twenty Years of Participation of Racialised Groups in Type 2 Diabetes Randomised Clinical Trials: A Meta\u2010Epidemiological Review","volume":"67","author":"Ahmed R.","year":"2024","journal-title":"Diabetologia"},{"issue":"12","key":"e_1_2_12_52_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, Ethnic, and Socioeconomic Inequities in Glucagon\u2010Like Peptide\u20101 Receptor Agonist Use Among Patients With Diabetes in the US","volume":"2","author":"Eberly L. A.","year":"2021","journal-title":"JAMA Health Forum"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70351","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.70351","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:52:53Z","timestamp":1790830373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/edm2.70351"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70351","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70351"}}